Can Indraprastha Medical Maintain Its Growth Momentum Amid Rising Costs?
About Indraprastha Medical
Indraprastha Medical Corporation, which operates the Apollo Hospitals in Delhi and NCR, is one of North India’s most reputed multi-speciality hospital networks. The company provides tertiary and quaternary care services across critical specialities, driven by steady patient inflows, strong brand recall, and operational excellence.
In Q2 FY26, the company reported moderate year-on-year growth, supported by higher occupancy levels and increased procedural revenues. However, on a sequential basis, margins and profitability softened slightly due to higher operating expenses and cost inflation.
Financial Highlights (Q2 FY26)
| Metric | Q2 FY26 | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹381 Cr | +9% | +4% |
| EBITDA | ₹71.3 Cr | +12% | -2% |
| EBITDA Margin | 18.7% | vs 18.2% | vs 20.0% |
| Net Profit | ₹49.5 Cr | +17% | -4% |
Revenue ₹381 Cr represents the income earned from hospital operations and diagnostic services during the quarter. Growth was supported by higher patient footfall and improved case mix.
EBITDA ₹71.3 Cr indicates operational profit before finance and depreciation. Despite higher costs, EBITDA improved YoY due to efficiency measures and better bed occupancy.
EBITDA Margin 18.7% means the hospital retained ₹18.7 as operational profit for every ₹100 of revenue, reflecting cost discipline and pricing stability.
Net Profit ₹49.5 Cr reflects post-tax earnings. Sequential dip of 4% was driven by higher expenses, though YoY profit remains healthy at +17%.
For short-term positional setups in the healthcare sector, traders can follow the Swing Trade Tip shared by our research team.
Peer Comparison
| Company | Revenue (₹ Cr) | EBITDA Margin |
|---|---|---|
| Indraprastha Medical | 381 | 18.7% |
| Apollo Hospitals | 5,500 | 13–14% |
| Max Healthcare | 1,400 | 22–24% |
While Indraprastha’s margin is slightly below Max Healthcare, it remains healthy and stable relative to peers, reflecting efficient hospital management.
SWOT Analysis
Strengths
|
Weaknesses
|
While operating costs are high due to location and scale, long-term brand strength continues to provide pricing power.
Opportunities
|
Threats
|
Increased patient footfall and new diagnostic services will likely support steady growth, though pricing regulation remains a key industry challenge.
Valuation & Investment View
- Short-term: Stable outlook as operational metrics remain consistent.
- Medium-term: Margin normalization expected as cost pressures ease.
- Long-term: Strong patient trust and medical infrastructure provide sustained value creation potential.
For portfolio-linked healthcare strategies, investors may review the F&O Strategy framework for long-horizon allocations.
Indraprastha Medical continues to deliver steady performance, supported by strong occupancy, brand reliability, and prudent financial management.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Registered Investment Adviser, highlights that Indraprastha Medical’s moderate growth, stable margins, and brand-led moat make it a steady compounder in the healthcare space. Investors may consider accumulating on corrections for medium-term gains. Explore more such insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Indraprastha Medical Results
- What caused the sequential margin decline in Q2 FY26?
- How does Indraprastha’s performance compare with Max Healthcare?
- What are the key growth drivers for FY26 in hospital operations?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
